Technical Analysis for LXEO - Lexeo Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 6.65 | -14.52% | -1.13 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | -14.52% | |
| Wide Bands | Range Expansion | -14.52% | |
| Oversold Stochastic | Weakness | -14.52% | |
| 20 DMA Resistance | Bearish | -12.96% | |
| 50 DMA Resistance | Bearish | -12.96% | |
| New 52 Week Closing Low | Bearish | -12.96% |
| Alert | Time |
|---|---|
| Down 10% | 2 days ago |
| 2x Volume Pace | 2 days ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| 1.5x Volume Pace | 2 days ago |
| Down 5% | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 02/28/2024
Lexeo Therapeutics, Inc. Description
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020 to treat ARVC caused by mutations in the PKP2 gene; LX2021 to treat DSP Cardiomyopathy associated with Cx43 deficiency; and LX2022 to treat HCM associated with mutations in the TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of POE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Rare Diseases Gene Therapy Applied Genetics Cardiomyopathy Lipid Storage Disorders Ataxia Friedreich's Ataxia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 22.33 |
| 52 Week Low | 6.65 |
| Average Volume | 471,342 |
| 200-Day Moving Average | 12.89 |
| 50-Day Moving Average | 9.01 |
| 20-Day Moving Average | 8.59 |
| 10-Day Moving Average | 7.81 |
| Average True Range | 0.93 |
| RSI (14) | 31.03 |
| ADX | 24.01 |
| +DI | 32.99 |
| -DI | 21.82 |
| Chandelier Exit (Long, 3 ATRs) | 8.94 |
| Chandelier Exit (Short, 3 ATRs) | 9.43 |
| Upper Bollinger Bands | 10.70 |
| Lower Bollinger Band | 6.48 |
| Percent B (%b) | 0.04 |
| BandWidth | 49.20 |
| MACD Line | -0.55 |
| MACD Signal Line | -0.42 |
| MACD Histogram | -0.1251 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.60 | ||||
| Resistance 3 (R3) | 8.82 | 8.38 | 8.28 | ||
| Resistance 2 (R2) | 8.38 | 7.89 | 8.28 | 8.17 | |
| Resistance 1 (R1) | 7.52 | 7.58 | 7.30 | 7.30 | 8.06 |
| Pivot Point | 7.08 | 7.08 | 6.98 | 6.98 | 7.08 |
| Support 1 (S1) | 6.22 | 6.59 | 6.00 | 6.00 | 5.24 |
| Support 2 (S2) | 5.78 | 6.28 | 5.68 | 5.13 | |
| Support 3 (S3) | 4.92 | 5.78 | 5.03 | ||
| Support 4 (S4) | 4.70 |
